Rebecca Dodd
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (63)
Year:
2026
Histone deacetylases (HDAC) regulate diverse pathways in cancer cells. Previously, we identified that Ewing sarcoma tumors, which are caused by a translocation between the EWSR1 and FLI1 genes (EWS::FLI1), are sensitive to drugs that target DNA replication, including the RRM1 and RRM2 subunits of ribonucleotide reductase, and the ATR–checkpoint kinase 1 (CHK1)–WEE1 signaling pathway. In this study, we identified that multiple HDAC inhibitors, including fimepinostat, romidepsin, and panobinostat, downregulate the levels of the RRM1, RRM2, CHK1, and WEE1 proteins in Ewing sarcoma cells and impair DNA replication. Moreover, transcriptome analyses identified that HDAC inhibitors downregulate the expression of multiple components of the prereplication complex, including the minichromosome maintenance complex 2–7 (MCM2–7) proteins and CDT1, that are essential for genomic DNA replication. Additionally, proteomic studies identified that HDAC inhibitors also downregulate the level of the BRD4 protein, a BET bromodomain protein that regulates both the transcriptional program of the EWS::FLI1 oncoprotein and DNA replication. Overall, these results provide novel insight into the molecular mechanisms by which HDAC inhibitors target cancer cells, regulate DNA replication, and inhibit the cellular response to DNA replication stress. Significance: In this work, we identify that HDAC inhibitors broadly disrupt DNA replication and the response to replication stress in Ewing sarcoma cells by downregulating RRM1, RRM2, CHK1, and WEE1. Notably, HDAC inhibitors also reduce MCM2–7 proteins, which are essential for prereplication complex helicase function in replication initiation and elongation, and CDT1, which loads MCM2–7 onto DNA.
Year:
2025
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive and chemo-resistant sarcomas with poor survival rates. Loss of CDKN2A or P53 following NF1 disruption is a key event in MPNST development. Here, we used CRISPR-Cas9 somatic tumorigenesis in mice to identify transcriptomic and metabolomic features distinguishing CDKN2A - versus P53 -deleted MPNSTs. Convergent, multiomic analyses revealed that CDKN2A -deleted MPNSTs are especially dependent on the pentose phosphate pathway (PPP) and NADPH metabolism for growth and viability. Disruption of glucose-6-phosphate dehydrogenase (G6PD), the PPP rate-limiting enzyme, slowed CDKN2A -deleted MPNST growth and sensitized MPNSTs to standard-of-care chemotherapy. Knockdown of the redox-regulated transcription factor NRF2 slowed MPNST growth and decreased G6PD transcription. Analysis of patient MPNSTs identified a NRF2 gene signature correlating with tumor transformation. Furthermore, G6PD and NRF2 expression in PanCancer TCGA samples correlates with patient survival. This work identifies NRF2-PPP dependency as a targetable vulnerability in these difficult-to-treat MPNSTs, particularly in the NF1/CDKN2A -deleted majority.
Year:
2025
Protein arginine methyltransferase 5 inhibitors represent a promising therapeutic approach for multiple cancers, but their clinical development is hindered by toxicity to normal cells. Synthetic lethality approaches using MTAP-cooperative protein arginine methyltransferase 5 inhibitors offer a compelling strategy that selectively targets cancer cells in nerve sheath sarcomas and other MTAP-deleted tumors. See related article by Zhang et al., p. 4779
Year:
2025
The incidence of colorectal cancer in young adults (age of diagnosis Significance: We investigated whether environmentally driven factors contribute to EOCRC. We observed accelerated epigenetic aging in EOCRC and epigenetic changes associated with chronic inflammation. Tumor immune cell abundances correlated more strongly with microbes in EOCRC than in AOCRC. These data suggest a dysregulation of the immune response in EOCRC, driving chronic inflammation and tissue aging.
Year:
2025
Relationship between microbes and immune cell composition. A, All microbe-genus level abundances (columns) correlated to the deconvolved immune cell abundances (rows), with the strength of the association and its direction indicated by color in the TCGA (top row) and ORIEN (bottom row) datasets. Spearman correlations between the deconvolved abundance of ( B ) activated mast cells or ( C ) neutrophils and microbes in both the TCGA and ORIEN datasets. Concordant associations (significant in both and in the same direction) are shown in green, with select taxa labeled. There were no microbes significantly anticorrelated with activated mast cells or neutrophils.
Year:
2025
Accelerated aging with epigenetic signatures in EOCRC. A, Heatmap was drawn with samples (patients) in the row and CpG sites (probes) in the column. The DNAm values range from 0.0 (completely unmethylated, blue) to 1.0 (completely methylated, red). B, The volcano plot demonstrated differential methylated sites (expressed as β values) between EOCRC and AOCRC groups. △β for each CpG site is defined as β value of (EOCRC – AOCRC). FDR-adjusted P P value P value C, Box plot showed the mean β value of patients with EOCRC and AOCRC was 0.46 ± 0.028 and 0.47 ± 0.027 ( P value = 0.13, two-sample t test), respectively. D, Box plots demonstrated the accelerated aging in EOCRC. The DNAm age acceleration (Δ = methylation age − chronologic age) in EOCRC and AOCRC for all samples is shown. The Δ EOCRC predicted by Horvath, Hannum, and PhenoAge models was 2.1, 18.4, and 32.8 years, respectively. The Δ AOCRC predicted by Horvath, Hannum, and PhenoAge was −14.2, 3.4, and 27.1 years, respectively, with P values of 7.89E−12, 1.48E−08, and 0.17, respectively.
Year:
2025
Intratumoral microbes do not show consistent differences in EOCRC. A, Venn diagram demonstrated partial overlap in microbes among three datasets. The abundances of observed genera that passed stringent quality and contamination filters are shown (ORIEN, n = 353 genera; TCGA, n = 357 genera; and 16S, n = 30 genera), with the best agreement between the two RNA-seq datasets. B, The Bray–Curtis dissimilarity plot showed that RNA-seq–derived microbes were most similar to 16S microbes from the same tumor (paired) and least similar to microbes from adjacent normal tissue from another person (unpaired). C, The comparison of the relative abundance of microbes between the 16S-based dataset and the RNA-seq–based datasets (ORIEN and TCGA). D–F, Volcano plots showed no consistent differences in microbes from RNA-seq–based (TCGA, ORIEN) or 16S-based datasets. No microbes passed the significance threshold in EOCRC. G–I, Effect sizes of the most significant taxa across the three analyses showed no similarities in the AOCRC-enriched microbes.
Year:
2025
Methylation signature validation through GE profiles in EOCRC. A, Integration of the differentially methylated sites with paired RNA-seq showed genes that vary in methylation and transcription. The threshold for the FDR-adjusted P values for differences is 0.05 (FDR P value ≤ 0.05). Highlighted genes in orange indicate significant hypomethylation and expression. B, The canonical pathways involved with DMGs in EOCRC have an FDR-adjusted P value C and D, Bubble chart of pathways based on DEGs in EOCRC from TCGA and ORIEN, highlighting those predicted by methylation alone. The color of the pathways is based on their z -score, and the size of the bubble is correlated with the number of genes from the dataset that overlap each pathway. E, Summary of the analyses to validate the differential methylation, with those supported by all three datasets indicated within the box.
Year:
2025
HDAC inhibitors decrease RRM1, RRM2, CHK1, and WEE1 protein levels. A, EW8 and TC71 cells were treated with fimepinostat (25 or 100 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting. B, EW8 and TC71 cells were treated with LY3023414 (1,000 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting. C, EW8 and TC71 cells were treated with panobinostat (10 nmol/L) or romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting. D and E, EW8 cells were treated with different doses of panobinostat ( D ) or romidepsin ( E ) for 24 hours, and then cellular lysates were collected for immunoblotting. F, Cell lines representing additional sarcoma subtypes were treated with romidepsin (5 nmol/L) for 24 hours, and then cellular lysates were collected for immunoblotting.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2020
Year:
2020
Year:
2020
Collaborators (41)
Jessica Zimmerman
Assistant Professor
Iowa State University
Eric Singer
Professor
The Ohio State University Wexner Medical Center
Jiangjiang Zhu
Ohio State University
Christine A Pratilas
Vice Chair for Pediatric Oncology
Johns Hopkins University School of Medicine
Jessica Sieren
Associate Professor
Iowa State University
Amy Tang
Tenured Professor
Eastern Virginia Medical School
Gregory Riedlinger
Rutgers Cancer Institute of New Jersey
Dawn Quelle
Professor
Iowa State University
Nicholas Denko
Professor
Ohio State University
Deng Fu Guo
Research associate scientist
The University of Iowa
David Meyerholz
Professor
The University of Iowa Roy J and Lucille A Carver College of Medicine
Aik Choon Tan
Senior Director of Data Science
Huntsman Cancer Institute
Adam Rauckhorst
Assistant Professor of Cellular and Molecular Medicine
Florida International University
Munir Tanas
Professor
The University of Iowa
Fouad Choueiry
Ohio State University
Nicholas Borcherding
Assistant Professor
University of Washington Medical Center
Ning Jin
Associate Proffessor
Ohio State University
Martin D. McCarter
Professor
University of Colorado Anschutz Medical Campus
Alexandra Isaacson
Clinical Assistant Professor
University of Iowa Hospitals and Clinics
Carlos HF Chan
Emory University
Matthew Kalady
Professor
Ohio State University
John D. Carpten
City of Hope Comprehensive Cancer Center
Alexandra Ikeguchi
Associate Professor
The University of Texas MD Anderson Cancer Center
Patrick Breheny
Professor
The University of Iowa
Gabriel Tinoco
Associate Professor of Medicine
Ohio State University
Benjamin Darbro
Professor
The University of Iowa
Anjun Ma
Assistant Professor
Ohio State University
Angela C. Hirbe
Washington University School of Medicine
Sheetal Hardikar
University of Utah
Qin Ma
Vice Chair for Research
Ohio State University
Yousef Zakharia
Mayo Clinic Arizona
Dan Spakowicz
Assistant Professor
The Ohio State University Comprehensive Cancer Center
Varun Monga
Clinical Associate Professor
University of California San Francisco Medical Center
David Gordon
Associate Professor
Iowa State University
Daniel W. Rosenberg
University of Connecticut Health Center
Xiaokui Mo
Research Scientist
Ohio State University
Douglas Spitz
Professor
The University of Iowa
Ahmad Tarhini
Senior Member, Professor
H Lee Moffitt Cancer Center and Research Institute
Griffin Caryotakis
Huntsman Cancer Institute
Caroline Dravillas
Ohio State University
YunZhou Liu
Ohio State University
Make your next move.
Prepare your application
Review drafts before you send them.